Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL499056 | 1.00 | REN (0.55) | RENCYP3A4 | |
| SCHEMBL499127 | 0.88 | REN (0.53) | RENCYP3A4 | |
| SCHEMBL499126 | 0.88 | REN (0.53) | RENCYP3A4 | |
| SCHEMBL2998864 | 0.82 | REN (0.55) | RENCYP3A4 | |
| SCHEMBL3004738 | 0.82 | REN (0.55) | RENCYP3A4 | |
| SCHEMBL10253830 | 0.80 | REN (0.63) | RENCYP3A4 | |
| SCHEMBL8082213 | 0.80 | REN (0.63) | RENCYP3A4 | |
| SCHEMBL4753659 | 0.78 | REN (0.42) | RENCYP3A4 | |
| SCHEMBL2998810 | 0.78 | REN (0.69) | RENCYP3A4 | |
| SCHEMBL2996644 | 0.78 | REN (0.69) | RENCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008156816-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | claimed |
| US-8106221-B2 | Renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20100144825-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144825-A1 | Renin Inhibitors | ACE, REN, DNPEP | REN 2/4885CYP3A4 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.